<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897997</url>
  </required_header>
  <id_info>
    <org_study_id>20210502VandoeuvreFranceEurope</org_study_id>
    <nct_id>NCT04897997</nct_id>
  </id_info>
  <brief_title>Effect of Smoking on Activated Clotting Time Values During Coronarography and Angioplasty</brief_title>
  <official_title>Effect of Smoking on Activated Clotting Time Values During Coronary Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      analyzing influence of smoking on patients anti-coagulation status as assessed by ACT&#xD;
      measurements during coronary angioplasty&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During angioplasty, activated clotting time (ACT) measurements are recommended to attest the&#xD;
      correct anticoagulation level and if anticoagulation levels are suboptimal after the two&#xD;
      first boluses, additional unfractionated heparin (UFH) injections are recommended until&#xD;
      obtention of a therapeutic ACT values (250-350s).&#xD;
&#xD;
      The study hypothesis was that the procoagulant effect of the tobacco may be responsible of&#xD;
      reduced anticoagulation levels after standardized UFH administrations and thus presenting an&#xD;
      UFH resistance requiring increased UFH dosages to obtain a therapeutic ACT values.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACT values after injection the first injection of a standardized unfractionated heparin bolus between non-smoking and actively smoking patients</measure>
    <time_frame>during the intervention</time_frame>
    <description>comparison of ACT values after injection of two standardized UFH boluses between non-smoking and actively smoking patients (non-smoker group versus active smoker group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACT values after injection the second injection of a standardized unfractionated heparin bolus between non-smoking and actively smoking patients</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>comparison of ACT values after injection of two standardized UFH boluses between non-smoking and actively smoking patients (non-smoker group versus active smoker group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACT values after injection of the first standardized UFH bolus in ex-smokers</measure>
    <time_frame>during the intervention</time_frame>
    <description>ACT values after injection of the first standardized UFH bolus in ex-smokers requiring a coronarography followed by a PTCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACT values after injection of the second standardized UFH bolus in ex-smokers</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>ACT values after injection of the second standardized UFH bolus in ex-smokers requiring a coronarography followed by a PTCA</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>non smokers</arm_group_label>
    <description>never having smoked patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>smokers</arm_group_label>
    <description>actively smoking patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acute coronary syndrome</arm_group_label>
    <description>patients with the coronary indication of ACS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stable</arm_group_label>
    <description>patients with the coronary indication of stable or silent ischemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronarography and angioplasty</intervention_name>
    <description>selective angiography of the coronaries and angioplasty of significant culprit lesion(s)</description>
    <arm_group_label>acute coronary syndrome</arm_group_label>
    <arm_group_label>non smokers</arm_group_label>
    <arm_group_label>smokers</arm_group_label>
    <arm_group_label>stable</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sampling&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        any patient needing a coronarography followed by an angioplasty without the above mentioned&#xD;
        exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any patient older than 18 years needing a diagnostic coronarography was eligible for&#xD;
             enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unconscious patient&#xD;
&#xD;
          -  any patient presenting with one of the following characteristic known to impact either&#xD;
             on ACT or aPTT measurements as: oral anticoagulation medication (anti-vitamin K and&#xD;
             non-vitamin K antagonist oral anticoagulants [NOAC]), fondaparinux or LMWH usage,&#xD;
             coagulopathy defined as prothrombin time &lt; 50 % or thrombopenia &lt; 50 000 G/L, declared&#xD;
             or observed thrombophilia defined as antithrombin &lt; 50%, baseline aPTT values with a&#xD;
             ratio patient/control &gt; 1.2 presence of lupus anticoagulant, connective tissue&#xD;
             disease, active cancer&#xD;
&#xD;
          -  a person as defined by the law articles L. 1121-5, L. 1121-7 et L1121-8 of the Code de&#xD;
             la santé publique, France (pregnant, parturient women or breastfeeding women, legally&#xD;
             adult patient under legal protection measure [tutelage, protection of vulnerable&#xD;
             adults]),&#xD;
&#xD;
          -  a person as defined by the law articles L. 3212-1 et L. 3213-1 of the Code de la santé&#xD;
             publique, France (legally adult patient unable to consent, person with legal or&#xD;
             administrative freedom restriction or person under psychiatric treatment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Edoardo Camenzind, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Nancy France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edoardo Camenzind, Professor</last_name>
    <phone>+33 3 83 15 5339</phone>
    <email>edoardo@camenzind-cardio.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Régis Trimole, MD</last_name>
    <phone>+33 6 02 37 4187</phone>
    <email>trimole.regis@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Nancy Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Adam</last_name>
      <phone>+33 3 83 15 3296</phone>
      <email>s.adam@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pr Camenzind</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

